Sinopharm Capital
Asia, Shanghai, China, Shanghai'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)
Description
Sinopharm Capital is a private equity arm of China National Pharmaceutical Group Corporation.
Investor Profile
Sinopharm Capital has backed more than 6 startups, with 0 new investments in the last 12 months alone. The firm has led 2 rounds, about 33% of its total and boasts 9 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series B, Series C, Series A rounds (top funding stages).
- Majority of deals are located in United States, China.
- Strong thematic focus on Health Care, Medical, Biotechnology.
Stage Focus
- Series B (67%)
- Series C (17%)
- Series A (17%)
Country Focus
- United States (50%)
- China (50%)
Industry Focus
- Health Care
- Medical
- Biotechnology
- Medical Device
- Robotics
- Clinical Trials
- Therapeutics
- Artificial Intelligence (Ai)
- Big Data
- Cloud Computing
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
'/%3e%3cuse xlink:href='%23a' transform='rotate(144 450 300)'/%3e%3cuse xlink:href='%23a' transform='rotate(216 450 300)'/%3e%3cuse xlink:href='%23a' transform='rotate(288 450 300)'/%3e%3c/svg%3e)
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
